NewLimit develops longevity therapeutics to extend human healthspan through cellular reprogramming.
$435MSeries C
A $435M Series C for cellular reprogramming signals that longevity is moving from research curiosity to venture-scale commercialization—Founders Fund doesn't deploy this size on moonshots anymore. NewLimit likely uses this to fund manufacturing scale and early clinical trials, which means the real bottleneck isn't science validation but regulatory pathway and cost-per-dose. If you're building in adjacent biotech (gene therapy, synthetic biology, diagnostics), watch how NewLimit navigates FDA timelines—their playbook becomes the template for other 'too early' categories trying to compress 15-year development cycles.